These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 19574692)

  • 1. Current concepts in the pathophysiology of glaucoma.
    Agarwal R; Gupta SK; Agarwal P; Saxena R; Agrawal SS
    Indian J Ophthalmol; 2009; 57(4):257-66. PubMed ID: 19574692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG).
    Dreyer EB; Grosskreutz CL
    Clin Neurosci; 1997; 4(5):270-3. PubMed ID: 9292254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of primary open-angle glaucoma from a neuroinflammatory and neurotoxicity perspective: a review of the literature.
    Evangelho K; Mogilevskaya M; Losada-Barragan M; Vargas-Sanchez JK
    Int Ophthalmol; 2019 Jan; 39(1):259-271. PubMed ID: 29290065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From ocular hypertension to ganglion cell death: a theoretical sequence of events leading to glaucoma.
    Nickells RW
    Can J Ophthalmol; 2007 Apr; 42(2):278-87. PubMed ID: 17392853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glaucoma as a dangerous interplay between ocular fluid and cerebrospinal fluid.
    Wostyn P
    Med Hypotheses; 2019 Jun; 127():97-99. PubMed ID: 31088658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual function-specific perimetry for indirect comparison of different ganglion cell populations in glaucoma.
    Sample PA; Bosworth CF; Blumenthal EZ; Girkin C; Weinreb RN
    Invest Ophthalmol Vis Sci; 2000 Jun; 41(7):1783-90. PubMed ID: 10845599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New insights into the pathogenesis of glaucomatous optic neuropathy and refinement of the objective assessment of its functional damage].
    Nakamura M
    Nippon Ganka Gakkai Zasshi; 2012 Mar; 116(3):298-344; discussion 345-6. PubMed ID: 22568105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New horizons in neuroprotection.
    Naskar R; Dreyer EB
    Surv Ophthalmol; 2001 May; 45 Suppl 3():S250-5; discussion S273-6. PubMed ID: 11377444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural compounds and retinal ganglion cell neuroprotection.
    Morrone LA; Rombolà L; Corasaniti MT; Bagetta G; Nucci C; Russo R
    Prog Brain Res; 2015; 220():257-81. PubMed ID: 26497795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent retinal ganglion cell loss, microglial activation and blood-retina-barrier tightness in an acute model of ocular hypertension.
    Trost A; Motloch K; Bruckner D; Schroedl F; Bogner B; Kaser-Eichberger A; Runge C; Strohmaier C; Klein B; Aigner L; Reitsamer HA
    Exp Eye Res; 2015 Jul; 136():59-71. PubMed ID: 26001526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The dawn of neuroprotective therapy for glaucomatous optic neuropathy].
    Yamamoto T
    Nippon Ganka Gakkai Zasshi; 2001 Dec; 105(12):866-83. PubMed ID: 11802458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ocular hypertension on the pattern of retinal ganglion cell subtype loss in a mouse model of early-onset glaucoma.
    Daniel S; Meyer KJ; Clark AF; Anderson MG; McDowell CM
    Exp Eye Res; 2019 Aug; 185():107703. PubMed ID: 31211954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy in axonal degeneration in glaucomatous optic neuropathy.
    Munemasa Y; Kitaoka Y
    Prog Retin Eye Res; 2015 Jul; 47():1-18. PubMed ID: 25816798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease progression and the need for neuroprotection in glaucoma management.
    Varma R; Peeples P; Walt JG; Bramley TJ
    Am J Manag Care; 2008 Feb; 14(1 Suppl):S15-9. PubMed ID: 18284311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glaucoma -state of the art and perspectives on treatment.
    Wójcik-Gryciuk A; Skup M; Waleszczyk WJ
    Restor Neurol Neurosci; 2016; 34(1):107-23. PubMed ID: 26684267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Microbead Occlusion Model of Ocular Hypertension in Mice.
    Calkins DJ; Lambert WS; Formichella CR; McLaughlin WM; Sappington RM
    Methods Mol Biol; 2018; 1695():23-39. PubMed ID: 29190015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.
    Chen YS; Green CR; Danesh-Meyer HV; Rupenthal ID
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):182-93. PubMed ID: 25676338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy in retinal ganglion cells in a rhesus monkey chronic hypertensive glaucoma model.
    Deng S; Wang M; Yan Z; Tian Z; Chen H; Yang X; Zhuo Y
    PLoS One; 2013; 8(10):e77100. PubMed ID: 24143204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Modern concepts in the pathogenesis and treatment of glaucoma].
    Nicoară S
    Oftalmologia; 2000; 51(2):9-13. PubMed ID: 11021117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.